could be predicated and prevented with pre-treatment. The raising of risk prediction models depends on the collection of patient phenotypes, which are scattered in various forms and very cumbersome.

In this study, we collected the largest database of complete medical record of inpatients of lupus in China. The clinical phenotype database was generated by using natural language processing (NLP) techniques, then lupus nephritis (LN) prediction model was built.

Methods A total of 14,439 SLE patients were collected from the rheumatology and immunology departments of 13 Chinese tertiary hospitals in this study, including 13 062 females (90.46%), with an average age of 33.4 years, and the time span of EMR (Electronic Medical Records) was from October 28, 2001 to March 31, 2017. It includes basic information about patients, physical examination, inspection and diagnostic information, etc. We designed a hybrid NLP system combined NLP technical and expert knowledge at the same time, which was named as Deep Phenotyping System (DPS), to extract all the phenotypic information recorded in EMR. Based on these standard formatted entities, the machine learning and deep learning prediction methods are used to predict the LN in SLE.

Results The DPS efficiently processed EMR data, and its accuracy, precision, and recall were each greater than 93%. It extracted 73 794 entities from 14,439 SLE cases, each with time attributes, and produced 18,785,000,640 entities. Thus, a LN prediction model was raised, which the likelihood of lupus patients without nephritis will develop lupus nephritis within half and one year can be predicted.) More than 35 000 phenotypes was used in this model and it was verified with independent samples. The best accuracy ACC and area under the curve (AUC) can be achieved 0.88 and 0.86 respectively.

Conclusions The comprehensive SLE phenotype database constructed by NLP greatly improves the research efficiency of lupus clinical phenotype. We first proposed a predictive model of lupus nephritis, which is high applicability and efficiency. The experimental results of good close and open testing fully demonstrate the authenticity and practicality of this database. The research process and method based on real world data are also applicable to predict other important complications of lupus.

Funding Source(s): None

293

A NOVEL CD3/BCMA BISPECIFIC ANTIBODY SELECTIVELY KILLS PLASMA CELLS IN BONE MARROW OF HEALTHY INDIVIDUALS WITH IMPROVED SAFETY

¹Wim van Schooten*, ²Kerstin Juelke, ³Suhasini Iyer, ¹Ben Buelow, ¹Roland Buelow, ⁴Dieter Volk. ¹Teneobio, Inc; ²Institute for Medical Immunology, Charité University of Medicine; ³Teneobio; ⁴Institute for Medical Immunology, Charité University of Medicine, Berlin, Germany

10.1136/lupus-2019-lsm.293

Background Autoantibodies play an important role in the pathogenesis of systemic lupus erythematosus (SLE). Plasma cells secrete these autoantibodies but are unfortunately refractory to conventional immunosuppressive treatments. B-cell Maturation Antigen (BCMA) is exclusively expressed on

mature B cells and, for that reason, is considered a good target for plasma cell depletion. Here, we analyze a promising therapeutic in development for Multiple Myeloma (MM), that could be used for the treatment for SLE. The antiCD3*BCMA bispecific antibody TNB-383B is in clinical trials for the treatment of MM. *In vitro* experiment showed that TNB-383B added to human bone marrow samples *ex vivo* induced a dose dependent lysis of BCMA-expressing plasma cells.

Methods Depletion of plasma cells by TNB-383B was tested using bone marrow samples extracted from bone retrieved of hip replacements. Human bone marrow mononuclear cells (n=10) were incubated with TNB-383B at increasing concentrations. The activity of TNB-383B was compared to a positive control antibody (PC), which has a BCMA-binding domain and an Fc region identical to TNB-383B, but binds to CD3 with stronger affinity. Bone marrow mononuclear cells were incubated for 18 hours with controls and TNB383B and samples were analyzed for plasma cell depletion (cells expressing CD19+, IgD-, IgM-, CD38++, CD27++) and T cell activation (CD69, CD107a, CD137, CD154). Cytokine production (IFN-, TNF, IL-2, IL-6, IL-12p70, IL-13, IL-4 and IL-10) was evaluated using multiplex.

Results TNB-383B effectively depleted plasma cells in bone marrow samples of healthy individuals undergoing hip replacement; more than 80% of BCMA expressing plasma cells were depleted after an overnight incubation with TNB-383B or a positive control. Analysis activation markers showed that TNB-383B activated T cells as evidenced by the expression of activation markers (CD69, CD154 or CD137) but only minimal cytokine production was observed.

Conclusions TNB-383B represents a novel immunotherapeutic with improved safety and efficacy for the treatment of pathogenic long-lived plasma cells. TNB-383B is in clinical trials for the treatment of Multiple Myeloma. TNB-383B could be an attractive treatment to prevent acute organ rejection in Panel Reactive Antibody (PRA) organ transplantation and autoimmune patients including Systemic Lupus Erythematosus. Teneobio anticipates to start testing TNB-383B in PRA patients by late 2019.

Funding Source(s): Teneobio, Inc.

294

IMMUNOPHENOTYPIC SUBGROUPS OF SLE DEFINED BY AUTOANTIBODIES, GENE EXPRESSION AND FLOW CYTOMETRIC ANALYSIS

¹Marta Aguilar Zamora*, ²Hui Lu, ²Danyang Li, ²Zoe Betteridge, ³Katie Dutton, ³Md Yuzaiful Md Yusof, ³Antonios Psarras, The MASTERPLANS Consortium, ⁴Ian N Bruce, ²Neil McHugh, ³Edward Vital. ¹Hospital Universitario Dr. Peset, Valencia. Fundación Valenciana de Reumatología; ²University of Bath; ³University of Leeds; ⁴University of Manchester

10.1136/lupus-2019-lsm.294

Background SLE may be stratified according to a range of different immune assessments but the relationships between these are less well defined. MASTERPLANS is an MRC-funded consortium that seeks to identify immunophenotypic subgroups of patients that predict response to therapy. Our objective here was to analyse a clinically well-phenotyped patients using a suite of immune assessments and identify inter-relationships